BB
ECYT

BB Biotech’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BB Biotech’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-683,522
Closed -$4.16M – 29
2014
Q3 		$4.16M Sell
683,522
-1,780,000
-72% -$12.2M 0.17% 25
2014
Q2 		$16.2M Hold
2,463,522
– – 0.77% 22
2014
Q1 		$58.7M Sell
2,463,522
-180,000
-7% -$2.61M 3.02% 12
2013
Q4 		$28.2M Buy
2,643,522
+374,177
+16% +$4.13M 1.51% 16
2013
Q3 		$30.3M Sell
2,269,345
-70,000
-3% -$1.11M 1.65% 16
2013
Q2 		$30.7M Buy
+2,339,345
New +$31.5M 2.21% 13

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BB Biotech's ECYT Position: Q4 2014 in Review

BB Biotech sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2014, closing a stake of 683,522 shares — an estimated $4.16M sold.

BB Biotech first reported a position in ECYT in Q2 2013 and held it in 6 quarters. The position peaked at $58.7M in Q1 2014. 100 funds tracked by Wall St. Rank hold ECYT as of Q4 2014.

  • BB Biotech reported no remaining Endocyte, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • BB Biotech sold 683,522 Endocyte, Inc. Common Stock shares in Q4 2014, an estimated $4.16M.
  • BB Biotech first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • BB Biotech's Endocyte, Inc. Common Stock position peaked at $58.7M in Q1 2014.
  • 100 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2014.

Based on BB Biotech's 13F filing for Q4 2014, filed 12 Feb 2015.